DIABETES RESEARCH CENTERS (P30): RFA-DK-06-012
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Letter of intent receipt date: June 26, 2006
Application receipt date: July 26, 2006
This request for applications (RFA) solicits new and competing continuation applications for Diabetes Endocrinology Research Centers (DERCs) and Diabetes Research and Training Centers (DRTCs). Both types of centers are designed to support and enhance the national research effort in diabetes and related endocrine and metabolic diseases. DERCs support three primary research-related activities: biomedical research cores, a pilot and feasibility program, and an enrichment program. DRTCs possess all the elements of a DERC, with additional dedicated core services and pilot and feasibility awards to support research in diabetes prevention and control. All activities pursued by diabetes centers are designed to enhance the efficiency, productivity, effectiveness, and multidisciplinary nature of research in Diabetes Center topic areas. The Diabetes Centers program in 2006 consists of 16 centers, each located at outstanding research institutions, with documented programs of research excellence in diabetes and endocrine and metabolic diseases. Information about the current Diabetes Centers can be found at the following URL: <http://www.niddk.nih.gov/fund/other/centers.htm#Endocrinology>. The total amount to be awarded under this RFA is up to $5.5 million for each of 5 years. The NIDDK anticipates awarding three Diabetes Center grants under this RFA. This RFA will use the NIH Core Centers (P30) and Comprehensive Centers (P60) grant award mechanisms. For-profit and nonprofit organizations are eligible, including public and private institutions, units of state and local governments, eligible agencies of the federal government, domestic and foreign institutions or organizations, and faith- or community-based organizations. Individuals with the skills, knowledge, and resources necessary to execute the functions proposed for a Diabetes Center are invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH programs. Investigating institutions may submit one Diabetes Center application in response to this RFA.
Complete details are available at <http://grants1.nih.gov/grants/guide/rfa-files/RFA-DK-06-012.html>.
PROGRAM PROJECTS FOR BASIC RESEARCH ON HUMAN EMBRYONIC STEM CELLS (P01): RFA-GM-07-002
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Letter of intent receipt date: September 6, 2006
Application receipt date: October 6, 2006
The goal of the proposed Program Project (P01) grants is to support research on the basic biology of human embryonic stem cells (hESCs) and to promote the use of hESCs as a model system to address significant questions in the basic biomedical sciences. The P01 should include a minimum of three R01-like subprojects to study the unique characteristics of hESCs and/or to use hESCs as a model system to address a basic biologic question. The P01 should include a core to grow, maintain, and further characterize approved hESC lines listed on the NIH Human Embryonic Stem Cell Registry, <http://stemcells.nih.gov/research/registry/>.
In addition, the core should serve as a resource to train investigators at the grantee institution to work with and use hESCs in pilot experiments. The core may also support research on improved growth and culture conditions of hESCs, compare the characteristics of hESC lines, and develop reagents and tools to enhance the use of hESCs as an experimental model system. The maximum total amount to be awarded for each application is $6.1 million, direct costs, for 5 years, with an anticipated amount of four awards to be made. This RFA uses the P01 Program Project mechanism. Eligible organizations include nonprofit organizations; public and private institutions, such as universities, colleges, hospitals, and laboratories; units of state and local government; eligible agencies of the federal government; and domestic institutions. Eligible principal investigators include any individual with the skills, knowledge, and resources necessary to carry out the proposed research. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH programs. Applicants may submit more than one application provided that they are scientifically distinct.
Complete details are available at <http://grants.nih.gov/grants/guide/rfa-files/RFA-GM-07-002.html>.
PILOT STUDIES IN PANCREATIC CANCER (R03): PA-06-314
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Opening date: May 2, 2006 (earliest date an application may be submitted to Grants.gov)
Application submission date: See http://grants1.nih.gov/grants/funding/submissionschedule.htm.
This funding opportunity is intended to promote innovative research across multiple disciplines for better understanding of the biology, etiology, detection, prevention, and treatment of pancreatic cancer.
Examples of appropriate research areas include but are not limited to identification of genetic aberrations (eg, mutations, epigenetic changes) or combinations of aberrations/alterations that initiate or promote pancreatic cancer; development of experimental models for human pancreatic cancer to facilitate the understanding of molecular carcinogenesis to help identify promising molecular targets and to test new preventive or therapeutic strategies; exploration of molecular pathways using human cell lines and/or tissues to identify possible novel targets for prevention or therapeutic development; identification of markers for early detection of cancer; conduct of preclinical studies to identify candidate chemopreventive drug(s) and dietary factors for prevention and to characterize the molecular mechanism(s) of the agent's activity; conduct of small exploratory clinical trials with a potential chemopreventive agent (eg, a farnesyltransferase inhibitor or a statin) assessing response via endoscopic ultrasonography or another similar technology; development of early-stage clinical trials in pancreatic cancer prevention and therapy; assessment of any associations of tumor pathophysiology on tumor development, progression, and preventive or therapeutic response; conduct of exploratory studies to identify and evaluate biomarkers (with associated assay development) to determine prognosis and predict response to therapy in pancreatic cancer; evaluation of combination therapies for pancreatic cancer; identification of new environmental exposures (eg, adverse energy balance) that may contribute to pancreatic cancer development, including adverse energy balance; assessment of the impact of pancreatic cancer on the health-related quality of life of patients and their caregivers; and conduct of pilot surveillance studies and generation of survivorship registries. Awards issued under this funding opportunity announcement (FOA) are contingent on the availability of funds and the submission of a sufficient number of meritorious applications; therefore, the anticipated number of awards is not known. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is intended to support small research projects that can be carried out in a short period of time with limited resources. Owing to the fact that the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend on the mechanism numbers, quality, duration, and costs of the applications received. Budgets for direct costs of up to $50,000 per year and a project duration of up to 2 years may be requested for a maximum of $100,000 direct costs over a 2-year project period. This FOA uses the NIH Small Grant (R03) mechanism and runs in parallel with an FOA of identical scientific scope, PA-06-303, which solicits applications under the NIH Exploratory/Developmental Grant (R21) award mechanism. Eligible organizations include for-profit and nonprofit organizations; public and private institutions, such as universities, colleges, hospitals, and laboratories; units of state, state tribal, local, and local tribal governments; eligible institutions of the federal government; domestic and foreign institutions; and faith- or community-based organizations. Eligible project directors or principal investigators include any individuals from the applicant institutions who have the skills, knowledge, and resources necessary to carry out the proposed research. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. Applicants may submit more than one application provided that each application is scientifically distinct.
For general information on SF424 (R&R) application and electronic submission, see the following Web sites:
SF424 (R&R) application and electronic submission information at http://grants.nih.gov/grants/funding/424/index.htm
General information on electronic submission of grant applications at http://era.nih.gov/ElectronicReceipt/
Notice: Applications submitted in response to this FOA for federal assistance must be submitted electronically through Grants.gov (<http://www.grants.gov>) using the SF424 research and related (R&R) forms and the SF424 (R&R) application guide.
Applications may not be submitted in paper format.
Complete details are available at <http://grants1.nih.gov/grants/guide/pa-files/PA-06-314.html>.
CROSS-DISCIPLINARY TRANSLATIONAL RESEARCH AT NIH (R21): PA-06-321
National Institutes of Health (NIH)
National Institute on Drug Abuse (NIDA)
National Cancer Institute (NCI)
Opening date: May 2, 2006 (earliest date an application may be submitted to Grants.gov)
Application submission/receipt date(s): Standard dates apply; see http://grants.nih.gov/grants/funding/submissionschedule.htm
The purpose of this funding opportunity announcement (FOA) is to foster research that furthers the translation of existing knowledge into treatment and treatment practice or research that, in and of itself, will readily translate to clinical research or practice. This FOA is intended to encourage projects that provide tools and resources that serve as platforms for the development of effective prevention and treatment strategies.
Owing to the fact that the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards are contingent on the availability of funds and the quality, duration, and costs of the applications received. This FOA will use the NIH Exploratory/Developmental Grant (R21) award mechanism and runs in parallel with an FOA of identical scientific scope, PA-06-322, which solicits applications under the Small Research Grant (R03) mechanism. Applicants wishing to submit applications under the traditional Research Project Grant (R01) mechanism are referred to the initial funding opportunity, PA-04-109. Regardless of the mechanism selected, interested applicants are advised to review PA-04-109 for additional information on the background and objectives of the initiative. The total project period for an application submitted in response to this funding opportunity may not exceed 2 years. Direct costs are limited to $275,000 over an R21 2-year period, with no more than $200,000 in direct costs allowed in any single year. Eligible organizations include for-profit organizations and nonprofit organizations; public and private institutions, such as universities, colleges, hospitals, and laboratories; units of state and local government; eligible agencies of the federal government; domestic and foreign institutions; faith- or community-based organizations; and units of state tribal and local tribal government. Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. Applicants may submit more than one application provided that each application is scientifically distinct.
The application instructions for this FOA are located at the following links:
http://grants.nih.gov/grants/funding/424/SF424-RR-Guide-General.doc (MS Word)
http://grants.nih.gov/grants/funding/424/SF424-RR-Guide-General.pdf (PDF)
For general information on SF424 (R&R) application and electronic submission, see the following Web sites:
SF424 (R&R) application and electronic submission information at http://grants.nih.gov/grants/funding/424/index.htm
General information on electronic submission of grant applications at http://era.nih.gov/ElectronicReceipt/
Notice: Applications submitted in response to this FOA for federal assistance must be submitted electronically through Grants.gov (<http://www.grants.gov>) using the SF424 research and related (R&R) forms and the SF424 (R&R) application guide.
Applications may not be submitted in paper format.
Complete details are available at <http://grants1.nih.gov/grants/guide/pa-files/PA-06-321.html>.
CROSS-DISCIPLINARY TRANSLATIONAL RESEARCH AT NIH (R03): PA-06-322
National Institutes of Health (NIH)
National Institute on Drug Abuse (NIDA)
National Cancer Institute (NCI)
Opening date: May 2, 2006 (earliest date an application may be submitted to Grants.gov)
Application submission/receipt date(s): Standard dates apply; see http://grants1.nih.gov/grants/funding/submissionschedule.htm.
The purpose of this funding opportunity announcement (FOA) is to foster research that furthers the translation of existing knowledge into treatment and treatment practice or research that, in and of itself, will readily translate to clinical research or practice.
Owing to the fact that the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards are contingent on the availability of funds and the quality, duration, and costs of the applications received. This funding opportunity will use the NIH Small Research Grant (R03) award mechanism and runs in parallel with an FOA of identical scientific scope, PA-06-321, which solicits applications under the Exploratory/Developmental Research Grant (R21) award mechanism. Applicants wishing to submit applications under the traditional Research Project Grant (R01) mechanism are referred to the initial funding opportunity, PA-04-109. Regardless of the mechanism selected, interested applicants are advised to review PA-04-109 for additional information on the background and objectives of the initiative. The R03 is intended to support small research projects that can be carried out in a short period of time with limited resources. The R03 is not renewable. Budgets for direct costs up to $50,000 per year and a project duration of up to 2 years may be requested for a maximum of $100,000 direct costs over a 2-year project period. Eligible organizations include for-profit and nonprofit organizations; public and private institutions, such as universities, colleges, hospitals, and laboratories; units of state and local governments; eligible agencies of the federal government; domestic and foreign institutions or organizations; faith- or community-based organizations; and units of state tribal and local tribal government. Eligible project directors or principal investigators include individuals with the skills, knowledge, and resources necessary to carry out the proposed research, who are invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. Applicants may submit more than one application provided that each application is scientifically distinct.
The application instructions for this FOA are located at the following links:
http://grants.nih.gov/grants/funding/424/SF424-RR-Guide-General.doc (MS Word)
http://grants.nih.gov/grants/funding/424/SF424-RR-Guide-General.pdf (PDF)
For general information on SF424 (R&R) application and electronic submission, see the following Web sites:
SF424 (R&R) application and electronic submission information at http://grants.nih.gov/grants/funding/424/index.htm
General information on electronic submission of grant applications at http://era.nih.gov/ElectronicReceipt/
Notice: Applications submitted in response to this FOA for federal assistance must be submitted electronically through Grants.gov (<http://www.grants.gov>) using the SF424 research and related (R&R) forms and the SF424 (R&R) application guide.
Applications may not be submitted in paper format.
Complete details are available at <http://grants1.nih.gov/grants/guide/pa-files/PA-06-322.html>.
CANCER PREVENTION RESEARCH SMALL GRANT PROGRAM (R03): PAR-06-313
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Opening date: May 2, 2006 (earliest date an application may be submitted to Grants.gov).
Application submission date(s): July 20, 2006; November 20, 2006; March 20, 2007; July 21, 2007; December 20, 2007.
The Division of Cancer Prevention of the NCI invites applications that address developmental research in chemoprevention agent development, biomarkers, early detection, and nutrition science. However, it is important to note that this funding opportunity does not include applications that are focused on treatment, etiology, or treatment-related quality of life studies that are population based. This Small Grants Program is designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of research expertise in cancer prevention research. It is anticipated that this Small Grant Program may lead to the submission of subsequent individual research project grants (R01). This funding opportunity announcement (FOA) will use the NIH Small Grant (R03) mechanism. The NIH R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is intended to support small research projects that can be carried out in a short period of time with limited resources. Budgets for direct costs of up to $50,000 per year and a project duration of up to 2 years may be requested for a maximum of $100,000 direct costs over a 2-year project period. Awards issued under this FOA are contingent on the availability of funds and the submission of a sufficient number of meritorious applications; therefore, the anticipated number of awards is not known. Owing to the fact that the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend on the mechanism numbers, quality, duration, and costs of the applications received. Eligible organizations include for-profit and nonprofit organizations; public and private institutions, such as universities, colleges, hospitals, and laboratories; units of state, state tribal, local, and local tribal governments; eligible institutions of the federal government; domestic and foreign institutions and organizations; and faith- or community-based organizations. Eligible project directors or principal investigators include individuals with the skills, knowledge, and resources necessary to carry out the proposed research, who are invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. New and experienced investigators in relevant fields and disciplines (eg, chemoprevention, nutritional science, genetics, infectious agents, and early detection, including biomarker development and validation) may apply for small grants to test ideas or do pilot studies. Applicants may submit more than one application provided that each application is scientifically distinct.
The SF424 research and related (R&R) application guide for this FOA is located at these Web sites:
http://grants1.nih.gov/grants/funding/424/SF424-RR-Guide-General.doc (MS Word)
http://grants1.nih.gov/grants/funding/424/SF424-RR-Guide-General.pdf (PDF)
For general information on SF424 (R&R) application and electronic submission, see the following Web sites:
SF424 (R&R) application and electronic submission information at http://grants.nih.gov/grants/funding/424/index.htm
General information on electronic submission of grant applications at http://era.nih.gov/ElectronicReceipt/
Notice: Applications submitted in response to this FOA for federal assistance must be submitted electronically through Grants.gov (<http://www.grants.gov>) using the SF424 R&R forms and the SF424 (R&R) application guide.
Applications may not be submitted in paper format.
Complete details are available at <http://grants1.nih.gov/grants/guide/pa-files/PAR-06-313.html>.
RESEARCH CENTERS OF EXCELLENCE IN PEDIATRIC NEPHROLOGY (P50): RFA-DK-06-011
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Letter of intent receipt date: October 24, 2006
Application receipt date: November 21, 2006
The emphases for this program are several-fold: (1) to continue to attract new scientific expertise into the study of the basic mechanisms of kidney diseases and disorders among infants, children, and adolescents; (2) to encourage multidisciplinary research focused on the causes of these diseases; (3) to explore new basic areas that may have clinical research application; and (4) to design developmental research or pilot and feasibility studies, which should lead to new and innovative approaches to study kidney disease in the pediatric population and the eventual submission of competitive investigator-initiated R01 research grant applications. These Centers complement the O'Brien Kidney and Urological Research Centers. The NIDDK plans to issue two awards, each at a maximum direct cost of $750,000 per year for 5 years. This request for applications will use the P50 mechanism. Eligible organizations include domestic for-profit and nonprofit organizations and public and private institutions. Eligible principal investigators include any individuals with the skills, knowledge, and resources necessary to carry out the proposed research. Applicant organizations may not submit more than one application.
Complete details are available at <http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-06-011.html>.
CYSTIC FIBROSIS RESEARCH AND TRANSLATION CORE CENTERS (P30): RFA-DK-06-009
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Letter of intent receipt date: June 20, 2006
Application receipt date: July 20, 2006
The Cystic Fibrosis Research and Translation Core Center Program is designed to support both basic and clinical research on cystic fibrosis (CF). Core Centers provide shared resources to support research to develop and test new therapies for CF and foster collaborations among institutions with a strong existing research base in CF. The Center will also support pilot and feasibility studies to develop and test new approaches to therapy. The NIDDK intends to commit $2,000,000 to this request for applications (RFA). The NIDDK anticipates issuing two awards. This RFA will use the NIH core center research grant (P30) award mechanism. Eligible organizations include for-profit and nonprofit organizations, public and private institutions, units of state and local governments, eligible agencies of the federal government, and domestic institutions. Eligible principal investigators include any individuals with the skills, knowledge, and resources necessary to carry out the proposed research. Applicant organizations may submit only one application to this RFA.
Complete details are available at <http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-06-009.html>.
HIGH-ACCURACY PROTEIN STRUCTURE MODELING (R01): RFA-GM-07-003
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Letter of intent receipt date: September 25, 2006
Application receipt date: October 23, 2006
The NIGMS invites applications for R01 research grants to support the development of novel technologies that will significantly improve the accuracy of comparative modeling methods for protein structure prediction. The total amount to be awarded is up to $1.6 million each year. Up to five awards are anticipated. The type of mechanism is an R01 research grant. The project period is limited to 3 years, with direct costs capped at $225,000 per year for each award. Eligible organizations include for-profit and nonprofit organizations, public and private institutions, units of state and local governments, and eligible agencies of the federal government. Domestic and foreign institutions are eligible to apply. Eligible principal investigators include individuals from eligible institutions who are qualified to carry out the proposed research. Applicant organizations may submit more than one application.
Complete details are available at <http://grants.nih.gov/grants/guide/rfa-files/RFA-GM-07-003.html>.
COLLABORATIVE STUDIES ON LUNG STEM CELL BIOLOGY AND CELL-BASED THERAPY (R01): RFA-HL-07-003
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Letter of intent receipt date: November 10, 2006
Application receipt date: December 12, 2006
The purpose of this request for applications is to foster research on lung stem cell biology and cell-based therapy for lung diseases. This program will support regular research grants (R01s), which include collaborations between basic scientists and clinical investigators who will explore together clinically relevant questions, thereby enabling basic science findings to be more readily translated into studies that investigate the potential of cell-based therapy for preventing and treating lung disease. An important goal of this program is to provide the basic knowledge necessary to eventually develop safe and efficacious clinical protocols on lung cell-based therapy. This funding opportunity will use the NIH R01 research grant award mechanism. The total amount to be awarded is $20 million over 4 years. A single application for a research grant application should not request more than $500,000 direct cost in any single year. The anticipated number of awards is six to seven. Eligible organizations include for-profit organizations; nonprofit organizations; and public and private institutions, such as universities, colleges, hospitals, and laboratories; foreign institutions and organizations are not eligible to apply. Although foreign institutions are not eligible to apply, foreign collaborators may participate in this program through subcontract(s) with domestic institutions. Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. Each applicant may submit only one application.
Complete details are available at <http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-07-003.html>.
INTEGRATING LUNG GENETICS AND GENOMICS IN HUMAN POPULATIONS (R01): PA-06-370
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI/NIH)
Application submission/receipt date(s): See http://grants1.nih.gov/grants/funding/submissionschedule.htm
The purpose of this initiative is to stimulate innovative approaches to merge genetic and genomic techniques to find genes associated with human complex traits for lung disease.
Owing to the fact that the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend on the mechanism numbers, quality, duration, and costs of the applications received. This program announcement will use the R01 mechanism. Eligible organizations include domestic and foreign institutions; for-profit and nonprofit organizations; public and private institutions, such as universities, colleges, hospitals, and laboratories; units of state and local governments; eligible agencies of the federal government; faith- or community-based organizations; Indian/Native American tribal governments (federally recognized and other than federally recognized); and Indian/Native American tribally designated organization. Eligible principal investigators include individuals with the skills, knowledge, and resources necessary to carry out the proposed research. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. Applicants may submit more than one application provided that they are scientifically distinct.
Complete details are available at <http://grants1.nih.gov/grants/guide/pa-files/PA-06-370.html>.
IN VIVO CANCER IMAGING EXPLORATORY/DEVELOPMENTAL GRANTS (R21): PA-06-371
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Opening date: May 2, 2006 (earliest date an application may be submitted to Grants.gov).
Note: On-time submission requires that applications be successfully submitted to Grants.gov no later than 5:00 pm local time (of applicant institution/organization).
Application submission date(s): See http://grants1.nih.gov/grants/funding/submissionschedule.htm#reviewandaward
The Cancer Imaging Program of the Division of Cancer Treatment and Diagnosis solicits exploratory/developmental (R21) applications that articulate high-risk and/or high-impact research focused on in vivo cancer imaging for the detection, diagnosis, and monitoring of response to therapy. Topics considered responsive to this funding opportunity announcement (FOA) will cover the entire spectrum of in vivo cancer imaging research, from basic discovery of new cancer imaging agents and technologies, through preclinical testing and validation, to the early feasibility testing of those novel agents and technologies in small clinical trials.
This FOA uses the NIH exploratory/developmental R21 grant mechanism only. The R21 is not renewable. The total project period for an application submitted in response to this FOA may not exceed 2 years. Direct costs are limited to $275,000 over an R21 2-year period, with no more than $200,000 in direct costs allowed in any single year. Owing to the fact that the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend on the quality, duration, and costs of the applications received. Eligible organizations include for-profit and nonprofit organizations; public and private institutions, such as universities, colleges, hospitals, and laboratories; units of state and local governments; eligible institutions of the federal government; domestic and foreign institutions; faith- or community-based organizations; Indian/Native American tribal governments (federally and other than federally recognized); and Indian/Native American tribally designated organizations. Eligible project directors or principal investigators include individuals with the skills, knowledge, and resources necessary to carry out the proposed research, who are invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. Applicants may submit more than one application provided that each application is scientifically distinct.
The SF424 (R&R) application guide for this FOA is located at these Web sites:
http://grants1.nih.gov/grants/funding/424/SF424-RR-Guide-General.doc (MS Word)
http://grants1.nih.gov/grants/funding/424/SF424-RR-Guide-General.pdf (PDF)
For general information on SF424 research and related (R&R) application and electronic submission, see the following Web sites:
SF424 (R&R) application and electronic submission information at http://grants.nih.gov/grants/funding/424/index.htm
General information on electronic submission of grant applications at http://era.nih.gov/ElectronicReceipt/
Notice: Applications submitted in response to this FOA for federal assistance must be submitted electronically through Grants.gov (<http://www.grants.gov>) using the SF424 (R&R) forms and the SF424 (R&R) application guide.
Applications may not be submitted in paper format.
Complete details are available at <http://grants1.nih.gov/grants/guide/pa-files/PA-06-371.html>.